Ikena Oncology (NASDAQ:IKNA) Receives “Neutral” Rating from Wedbush

Ikena Oncology (NASDAQ:IKNA)‘s stock had its “neutral” rating reaffirmed by Wedbush in a research note issued to investors on Thursday,RTT News reports. They currently have a $2.00 price objective on the stock. Wedbush’s target price suggests a potential upside of 18.34% from the company’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Ikena Oncology in a research note on Monday, August 12th.

Ikena Oncology Trading Down 1.7 %

Shares of NASDAQ IKNA traded down $0.03 during trading hours on Thursday, reaching $1.69. The stock had a trading volume of 47,045 shares, compared to its average volume of 247,592. The firm has a 50-day moving average of $1.70 and a 200-day moving average of $1.63. The firm has a market cap of $81.56 million, a price-to-earnings ratio of -1.19 and a beta of 0.48. Ikena Oncology has a fifty-two week low of $1.02 and a fifty-two week high of $4.16.

Ikena Oncology (NASDAQ:IKNA) last announced its earnings results on Thursday, August 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. On average, equities analysts predict that Ikena Oncology will post -1.03 EPS for the current year.

Hedge Funds Weigh In On Ikena Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. raised its stake in shares of Ikena Oncology by 813.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 513,440 shares of the company’s stock worth $729,000 after buying an additional 457,245 shares in the last quarter. Acadian Asset Management LLC grew its position in Ikena Oncology by 1,201.8% during the first quarter. Acadian Asset Management LLC now owns 282,782 shares of the company’s stock worth $400,000 after buying an additional 261,060 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Ikena Oncology during the 2nd quarter valued at approximately $36,000. BBR Partners LLC acquired a new stake in shares of Ikena Oncology in the 2nd quarter worth approximately $33,000. Finally, Sofinnova Investments Inc. raised its holdings in Ikena Oncology by 230.7% during the second quarter. Sofinnova Investments Inc. now owns 382,616 shares of the company’s stock worth $631,000 after purchasing an additional 266,904 shares during the last quarter. 75.00% of the stock is currently owned by hedge funds and other institutional investors.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.